|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2009-6-8
|
|
pubmed:abstractText |
Ovarian serous carcinomas (OSCs) comprise over half of all ovarian carcinomas and account for the majority of ovarian cancer-related deaths. We used a 2-dimensional liquid-based protein mapping strategy to characterize global protein expression patterns in 19 OSC tumor samples from 15 different patients to facilitate molecular classification of tumor stage. Protein expression profiles were produced, using pI-based separation in the first dimension and hydrophobicity-based separation in the second dimension, over a pH range of 4.0-7.0. Hierarchical clustering was applied to protein maps to indicate the tumor interrelationships. The 19 tumor samples could be classified into two different groups, one group associated with low stage (Stage 1) tumors and the other group associated with high stage (Stages 3/4) tumors. Proteins that were differentially expressed in different groups were selected for identification by LTQ-ESI-MS/MS. Fourteen of the selected proteins were overexpressed in the low stage tumors; 46 of the proteins were overexpressed in the high stage tumors. These proteins are known to play an important role in cellular functions such as glycolysis, protein biosynthesis, and cytoskeleton rearrangement and may serve as markers associated with different stages of OSCs. To further confirm the stage-dependent protein identifications, Lamin A/C and Vimentin expression in ovarian serous carcinomas was assessed by immunohistochemistry using ovarian tumor tissue microarrays for 66 samples.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19159301-10600311,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19159301-10918393,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19159301-11788994,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19159301-11943707,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19159301-11985308,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19159301-12183431,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19159301-12403597,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19159301-12438266,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19159301-12766576,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19159301-12782598,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19159301-12960427,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19159301-14996714,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19159301-14997480,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19159301-15020606,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19159301-15111296,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19159301-15172988,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19159301-15253663,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19159301-15274142,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19159301-15555543,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19159301-16141455,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19159301-16220531,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19159301-16288054,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19159301-16514137,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19159301-7617357,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19159301-7796418,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19159301-8898837,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19159301-9237175,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19159301-9400493
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1535-3893
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1452-63
|
|
pubmed:dateRevised |
2011-9-16
|
|
pubmed:meshHeading |
pubmed-meshheading:19159301-Amino Acid Sequence,
pubmed-meshheading:19159301-Cystadenocarcinoma, Serous,
pubmed-meshheading:19159301-Female,
pubmed-meshheading:19159301-Humans,
pubmed-meshheading:19159301-Immunohistochemistry,
pubmed-meshheading:19159301-Mass Spectrometry,
pubmed-meshheading:19159301-Molecular Sequence Data,
pubmed-meshheading:19159301-Ovarian Neoplasms,
pubmed-meshheading:19159301-Proteome,
pubmed-meshheading:19159301-Tumor Markers, Biological
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Differential protein mapping of ovarian serous adenocarcinomas: identification of potential markers for distinct tumor stage.
|
|
pubmed:affiliation |
Department of Chemistry, The University of Michigan, Ann Arbor, Michigan 48109, Department of Pathology, The University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural
|
